Biotech · Private company
Clinigen, Inc.
Track this companyFree. Adds Clinigen, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials63 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- High Dose Interleukin-2Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabMetastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- vemurafenib + HD IL-2Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.PHASE1 · RECRUITING · started Oct 20, 2022ClinicalTrials.gov NCT05547321 · fetched Nov 12, 2026
- IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 24, 2020ClinicalTrials.gov NCT04562129 · fetched Nov 12, 2026
- High Dose IL 2 and Entinostat in RCCPHASE2 · ACTIVE_NOT_RECRUITING · started May 24, 2018ClinicalTrials.gov NCT03501381 · fetched Nov 12, 2026
- HD IL-2 + Ipilimumab in Patients With Metastatic MelanomaPHASE4 · TERMINATED · started May 1, 2013ClinicalTrials.gov NCT01856023 · fetched Nov 12, 2026
- HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic MelanomaPHASE4 · TERMINATED · started Aug 1, 2012ClinicalTrials.gov NCT01683188 · fetched Nov 12, 2026
- A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)APPROVED_FOR_MARKETINGClinicalTrials.gov NCT04530994 · fetched Nov 12, 2026